@article{oai:repo.qst.go.jp:00048568,
 author = {Terasak, Fumio and Yoshinaga, Keiichiro and 吉永 恵一郎},
 issue = {1},
 journal = {Annals of Nuclear Cardiology　Volume3 No.1　August2017},
 month = {Aug},
 note = {In recent years, advancements in diagnostic imaging modalities, such as cardiac magnetic resonance (CMR) and 18F-fluorodeoxyglucose (18F-FDG) positron emission tomography (PET), as well as the accumulation of cases, have allowed a more accurate diagnosis of cardiac sarcoidosis (CS). In addition, emerging cases of “isolated CS” in which no obvious lesions are present in organs other than the heart have been reported, and the clinical importance of CS has become recognized. Many issues including etiology, pathology, diagnosis, and treatment of CS remain to be solved. Considering this situation, guidelines for the diagnosis and treatment of cardiac sarcoidosis were recently updated by the Japanese Circulation Society and were published in February 2017.},
 pages = {42--45},
 title = {New Guidelines for Diagnosis of Cardiac Sarcoidosis in Japan},
 volume = {3},
 year = {2017}
}